The development of new tools to combat bacterial infections was named as a top priority by President Obama in an executive order signed Thursday, Sept. 18, designed to address the growing problem of antibiotic resistance. As part of the executive order, the administration released the “National Strategy on Combating Antibiotic-Resistant Bacteria,” a five-year plan to prevent and contain outbreaks and develop the next generation of drugs, test and vaccines.
Ruthigen’s Chief Financial Officer Sameer Harish and I had the pleasure of speaking about Ruthigen’s new drug candidate, RUT58-60, before an audience of institutional investors, venture capitalists, private equity firms, private investors and industry executives at the Rodman & Renshaw 16th Annual Global Investment Conference, held Sept. 8 through 10 in New York City.
Few Americans alive today remember the days before the widespread use of vaccines and antibiotics when a respiratory infection that today would be considered little more than an inconvenience could lead to death and when outbreaks of childhood viruses such as measles could kill hundreds. The complacency about infectious diseases that has arisen throughout the developed world is now being jolted, however, by recent news about infectious diseases in general and specific outbreaks in particular.
Recently, the World Health Organization (WHO) announced that the rise and rapid spread of antibiotic-resistant bacteria raises threatens the achievements of modern medicine. “A post antibiotic era – in which common infections and minor injuries can kill — is a very real possibility for the 21st century,” the organization concluded.
British Prime Minister David Cameron warned earlier this month that the world is in danger of being thrust back into the dark ages of medicine unless action is taken to tackle to growing threat of antibiotic resistance. Cameron’s comments followed those last year from Dame Sally Davies, Britain’s chief medical officer, who warned Parliament that the rise in drug-resistant bacteria raised the prospect of a civil emergency. She described an “apocalyptic” scenario in which people undergoing simple operations in 20 years die of routine infections.
SANTA ROSA, Calif. — (June 12, 2014) — Ruthigen, Inc., (NASDAQ: RTGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, is pleased to announce today that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application without a clinical hold to begin human clinical testing of RUT58-60. Read More…